MNPR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States...

Stats
Today's Volume	38 738.00
Average Volume	5.50M
Market Cap	11.47M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.170 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.080
ATR14	$0.0120 (1.88%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Cittadine Andrew	Sell	8 952	Restricted Stock Units
2024-03-31	Cittadine Andrew	Buy	8 952	Common Stock
2024-03-31	Cittadine Andrew	Sell	3 098	Common Stock
2024-03-31	Tsuchimoto Kim R	Sell	9 956	Restricted Stock Units
2024-03-31	Tsuchimoto Kim R	Buy	9 956	Common Stock

INSIDER POWER
37.33
Last 100 transactions
Buy: 1 127 208 \| Sell: 341 037

Volume Correlation

Long: 0.03 (neutral)

Short: -0.16 (neutral)

Signal:(47.403) Neutral

Monopar Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Monopar Therapeutics Inc Correlation - Currency/Commodity

0.07
( neutral )

0.40
( neutral )

0.00
( neutral )

0.41
( neutral )

Monopar Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.610

Q4	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.120

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.140

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.